10 results about "Depression model" patented technology

The application provides an application of a motion-induced sweat extract in preparation of a medicine for treating, relieving or preventing depression and / or anxiety, and belongs to the field of biological medicine. Specifically, sweat is induced by making a healthy subject perform aerobic exercise of a specific intensity (such as 60%-80% of maximum heart rate), the sweat is collected and eluted by physiological saline, centrifuged and filtered to obtain a biologically active sweat extract. The extract is analyzed by transcriptomics and reverse transcription method to predict the anti-depression potential, and it is proved by in-vivo animal experiments that the extract can significantly improve the anhedonia, behavioral despair and anxiety-like behavior of a depression model mouse, and the effect of a high dose is equivalent to that of a first-line drug fluoxetine. The preparation raw material provided by the application is natural and safe, the preparation process is simple and the cost is low, and a new, easy-to-promote alternative strategy is provided for the prevention and treatment of depression.

The application discloses an application of NOD2 antagonist 1 in preparation of a medicine for preventing or treating depression, and belongs to the technical field of medicines. Specifically, the application relates to an application of a compound NOD2 antagonist 1 in preparation of a medicine for preventing or treating depression. The CAS registration number of the compound NOD2 antagonist 1 is 2411441-54-6. The application discloses a brand-new medicinal use of NOD2 antagonist 1, that is, the compound can be used for preparing a medicine for preventing or treating depression. Animal experiment results show that after intervention of NOD2 antagonist 1, the sucrose preference behavior of a depression model mouse is obviously improved, and depression-related emotional disorder performance is also obviously relieved. Based on the pharmacodynamic verification results, the technical scheme provided by the application has good clinical transformation and popularization and application prospects.

The application belongs to the technical field of biological medicine, and relates to a drug for treating depression, and in particular to application of cyclopentolate combined with esketamine in preparation of a drug for treating depression. Experimental researches of the application show that, compared with cyclopentolate or esketamine alone, cyclopentolate combined with esketamine can more significantly improve the depressive behavior of CRS depressive model mice, and it is proved that cyclopentolate combined with esketamine can synergistically enhance the anti-depression effect, so as to be used as a drug for treating depression.

This invention discloses the use of silybin derivatives or their stereoisomers, or pharmaceutically acceptable salts, with the structure shown in Formula I in the preparation of medicaments for the prevention and / or treatment of depressive disorders; R1, R2, R3, R4, R5, and R6 are independently selected from hydrogen, methyl, and methyl groups. Compared with silybin alone, royal jelly acid, or a combination of silybin and royal jelly acid, the silybin derivatives of this invention exhibit more significant effects on mouse models of depression induced by chronic social frustration stress and chronic restraint stress, even with significantly reduced dosage, and can be used to prepare medicaments for the treatment of depressive disorders.

The application discloses application of hippuric acid in preparation of a medicine for preventing and / or treating depression, and belongs to the technical field of biological medicine. The hippuric acid or pharmaceutically acceptable salt thereof has significant and multi-target antidepressant pharmacological activity through chronic mild stress depression animal model experiment. Specifically, in terms of improving core depressive symptoms, the sugar water preference experiment result shows that the hippuric acid can effectively reverse CUMS-induced hedonic deficiency of mice, and significantly improves the sucrose preference rate, and the forced swimming experiment proves that the hippuric acid can significantly shorten the immobility time of mice and relieve behavioral despair; in terms of improving anxiety-like behavior, the mine field experiment data show that after the hippuric acid intervention, the number of times of entering the central area, the residence time and the total activity distance of the depressive model mice are all significantly increased, which indicates that the hippuric acid can effectively improve the spontaneous activity reduction caused by chronic stress.

The application belongs to the field of medicine and relates to application of an isoflavone compound, isoformononetin (IFM), in preparation of a medicine or health care product for preventing and treating depression; in mouse hippocampal neuron cells (HT22) or mouse microglial cells (BV2), IFM can reduce neuroinflammation caused by corticosterone (CORT) or lipopolysaccharide (LPS) and increase the expression level of brain-derived neurotrophic factor (BDNF); in a chronic mild unpredictable stress mouse depression model, IFM can relieve depression-like behavior of the mouse and reduce the inflammation level of brain tissue, indicating that IFM has a good effect of relieving depression; IFM degrades PDE4D protein by directly combining with a PDE4D target protein. The isoflavone compound IFM has the advantages of outstanding effect and high safety and is expected to develop into an effective medicine for treating and preventing depression.

This invention discloses the application of a natural isoflavone compound in the preparation of drugs for the prevention or treatment of depression. The natural isoflavone compound is hematoxylin A, a derivative of hematoxylin A, or a pharmaceutically acceptable salt of hematoxylin A. Hematoxylin A can effectively reduce oxidative damage to HT22 neurons in the hippocampus induced by glutamate and corticosterone, and can significantly improve the behavioral performance of mice in a chronic restraint stress depression model, exhibiting clear antidepressant activity. Hematoxylin A has a well-defined structure and good safety profile, showing promising application prospects in the development of antidepressant drugs.

This invention belongs to the field of traditional Chinese medicine and natural product technology, specifically relating to the use of Leonurus japonicus extract in the preparation of antidepressant drugs. This invention uses 70% ethanol extraction to prepare Leonurus japonicus extract. This extraction method reduces extraction costs, shortens production time, increases extract yield, increases the extraction rate of effective components, and increases enterprise production efficiency. This invention also uses multiple depression models to verify the antidepressant activity of Leonurus japonicus extract, including a chronic unpredictable mild stress-induced depression model, a chronic corticosterone injection-induced depression model, and an ovariectomy combined with hormone withdrawal-induced depression model. The results show that Leonurus japonicus extract has a significant antidepressant effect in experimental animals. The antidepressant effect of the Leonurus japonicus extract of this invention is not obvious compared to the characteristics of traditional gynecological drugs, and it focuses on hormone-related depression, demonstrating the therapeutic value of Leonurus japonicus extract in the clinical classification of depression.

The application provides a traditional Chinese medicine composition for treating depression and application thereof, and relates to the technical field of traditional Chinese medicine pharmacy; the traditional Chinese medicine composition is composed of ten traditional Chinese medicines, namely, flowers of Chinese sweet gum, white daphne, cyperus rotundus, lycium ruthenicifolium, citrus medica, seven mile incense, saussurea lappa, zanthoxylum arms, radix zanthoxyli and lignum aquilariae resiniferum, and the combined use of the medicines has the effects of soothing liver and relieving depression and regulating and smoothing qi movement; the traditional Chinese medicine composition can improve the depressive behavior of a mouse with depression, significantly reduces the levels of inflammatory related factors IL-6, IL-1beta and TNF-alpha in serum of a mouse model with depression, and obviously improves the levels of monamine neurotransmitters 5-HT, DA and NE of the mouse; the traditional Chinese medicine composition can significantly reduce the HAMD score, PSQI score and TCM syndrome integral of a patient with depression, has a high total effective rate for treating depression, and provides a traditional Chinese medicine composition with remarkable effect and no toxic side effect for treating depression.